Showing results (2201-2210 of 2,272) with videos related to
Sort By:
Pageof 228
JAMA Oncology|August 12, 2021
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE TrialErika Martinelli, Giulia Martini, Vincenzo Famiglietti, et al.Journal of the American Academy of Child and Adolescent Psychiatry|August 2, 2007
Effects of stimulant medication on growth rates across 3 years in the MTA follow-upJames M Swanson, Glen R Elliott, Laurence L Greenhill, et al.Circulation. Heart Failure|April 24, 2026
Circulatory Support Escalation in Cardiogenic Shock Outcomes and Predictors of Successful Escalation from an International, Multi-Center Cardiac Intensive Care RegistryLuca Baldetti, Guglielmo Gallone, Jorge A Ortega-Hernandez, et al.Sleep|May 21, 2019
Effects on resident work hours, sleep duration, and work experience in a randomized order safety trial evaluating resident-physician schedules (ROSTERS)Laura K Barger, Jason P Sullivan, Terri Blackwell, et al.Journal of the American College of Surgeons|April 27, 2016
Perihilar Cholangiocarcinoma: Number of Nodes Examined and Optimal Lymph Node Prognostic SchemeFabio Bagante, Thuy Tran, Gaya Spolverato, et al.Sleep Medicine Reviews|August 17, 2024
To nap or not? Evidence from a meta-analysis of cohort studies of habitual daytime napping and health outcomesYing-Bo Yang, Yong-Bo Zheng, Jie Sun, et al.Journal of the American Academy of Child and Adolescent Psychiatry|October 28, 2009
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trialMichael G Aman, Christopher J McDougle, Lawrence Scahill, et al.Journal of the American Academy of Child and Adolescent Psychiatry|August 2, 2007
Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effectsBrooke S G Molina, Kate Flory, Stephen P Hinshaw, et al.European Journal of Cancer (Oxford, England : 1990)|August 21, 2020
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancerClaudia Cardone, Bernadette Blauensteiner, Veronica Moreno-Viedma, et al.The New England Journal of Medicine|June 25, 2020
Effect on Patient Safety of a Resident Physician Schedule without 24-Hour ShiftsChristopher P Landrigan, Shadab A Rahman, Jason P Sullivan, et al.Pageof 228